Chen Delphine L, Cheriyan Joseph, Chilvers Edwin R, Choudhury Gourab, Coello Christopher, Connell Martin, Fisk Marie, Groves Ashley M, Gunn Roger N, Holman Beverley F, Hutton Brian F, Lee Sarah, MacNee William, Mohan Divya, Parr David, Subramanian Deepak, Tal-Singer Ruth, Thielemans Kris, van Beek Edwin J R, Vass Laurence, Wellen Jeremy W, Wilkinson Ian, Wilson Frederick J
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri
Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
J Nucl Med. 2017 Feb;58(2):201-207. doi: 10.2967/jnumed.116.184796. Epub 2017 Jan 12.
Millions of people are affected by respiratory diseases, leading to a significant health burden globally. Because of the current insufficient knowledge of the underlying mechanisms that lead to the development and progression of respiratory diseases, treatment options remain limited. To overcome this limitation and understand the associated molecular changes, noninvasive imaging techniques such as PET and SPECT have been explored for biomarker development, with F-FDG PET imaging being the most studied. The quantification of pulmonary molecular imaging data remains challenging because of variations in tissue, air, blood, and water fractions within the lungs. The proportions of these components further differ depending on the lung disease. Therefore, different quantification approaches have been proposed to address these variabilities. However, no standardized approach has been developed to date. This article reviews the data evaluating F-FDG PET quantification approaches in lung diseases, focusing on methods to account for variations in lung components and the interpretation of the derived parameters. The diseases reviewed include acute respiratory distress syndrome, chronic obstructive pulmonary disease, and interstitial lung diseases such as idiopathic pulmonary fibrosis. Based on review of prior literature, ongoing research, and discussions among the authors, suggested considerations are presented to assist with the interpretation of the derived parameters from these approaches and the design of future studies.
数百万人受到呼吸系统疾病的影响,给全球带来了沉重的健康负担。由于目前对导致呼吸系统疾病发生和发展的潜在机制了解不足,治疗选择仍然有限。为了克服这一限制并了解相关的分子变化,人们探索了正电子发射断层扫描(PET)和单光子发射计算机断层扫描(SPECT)等非侵入性成像技术用于生物标志物的开发,其中氟代脱氧葡萄糖(F-FDG)PET成像的研究最为广泛。由于肺内组织、空气、血液和水分含量的变化,肺分子成像数据的定量分析仍然具有挑战性。这些成分的比例会因肺部疾病的不同而有所差异。因此,人们提出了不同的定量方法来解决这些变异性问题。然而,迄今为止尚未开发出标准化的方法。本文综述了评估F-FDG PET在肺部疾病中定量方法的数据,重点关注解决肺成分变化的方法以及对所得参数的解读。所综述的疾病包括急性呼吸窘迫综合征、慢性阻塞性肺疾病以及间质性肺疾病,如特发性肺纤维化。基于对既往文献、正在进行的研究以及作者之间讨论的回顾,提出了一些建议性的考量因素,以帮助解读这些方法所得出的参数以及设计未来的研究。